These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

982 related articles for article (PubMed ID: 16115903)

  • 1. Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
    Rouzier R; Perou CM; Symmans WF; Ibrahim N; Cristofanilli M; Anderson K; Hess KR; Stec J; Ayers M; Wagner P; Morandi P; Fan C; Rabiul I; Ross JS; Hortobagyi GN; Pusztai L
    Clin Cancer Res; 2005 Aug; 11(16):5678-85. PubMed ID: 16115903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
    Hess KR; Anderson K; Symmans WF; Valero V; Ibrahim N; Mejia JA; Booser D; Theriault RL; Buzdar AU; Dempsey PJ; Rouzier R; Sneige N; Ross JS; Vidaurre T; Gómez HL; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2006 Sep; 24(26):4236-44. PubMed ID: 16896004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial.
    Rody A; Karn T; Solbach C; Gaetje R; Munnes M; Kissler S; Ruckhäberle E; Minckwitz GV; Loibl S; Holtrich U; Kaufmann M
    Breast; 2007 Jun; 16(3):235-40. PubMed ID: 17449250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
    Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.
    Andre F; Job B; Dessen P; Tordai A; Michiels S; Liedtke C; Richon C; Yan K; Wang B; Vassal G; Delaloge S; Hortobagyi GN; Symmans WF; Lazar V; Pusztai L
    Clin Cancer Res; 2009 Jan; 15(2):441-51. PubMed ID: 19147748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
    Harris LN; You F; Schnitt SJ; Witkiewicz A; Lu X; Sgroi D; Ryan PD; Come SE; Burstein HJ; Lesnikoski BA; Kamma M; Friedman PN; Gelman R; Iglehart JD; Winer EP
    Clin Cancer Res; 2007 Feb; 13(4):1198-207. PubMed ID: 17317830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
    Lee JK; Coutant C; Kim YC; Qi Y; Theodorescu D; Symmans WF; Baggerly K; Rouzier R; Pusztai L
    Clin Cancer Res; 2010 Jan; 16(2):711-8. PubMed ID: 20068086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
    Tabchy A; Valero V; Vidaurre T; Lluch A; Gomez H; Martin M; Qi Y; Barajas-Figueroa LJ; Souchon E; Coutant C; Doimi FD; Ibrahim NK; Gong Y; Hortobagyi GN; Hess KR; Symmans WF; Pusztai L
    Clin Cancer Res; 2010 Nov; 16(21):5351-61. PubMed ID: 20829329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes.
    Jinno H; Matsuda S; Hayashida T; Takahashi M; Hirose S; Ikeda T; Kitagawa Y
    Chemotherapy; 2012; 58(5):364-70. PubMed ID: 23207824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
    Horak CE; Pusztai L; Xing G; Trifan OC; Saura C; Tseng LM; Chan S; Welcher R; Liu D
    Clin Cancer Res; 2013 Mar; 19(6):1587-95. PubMed ID: 23340299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
    Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.
    Folgueira MA; Carraro DM; Brentani H; Patrão DF; Barbosa EM; Netto MM; Caldeira JR; Katayama ML; Soares FA; Oliveira CT; Reis LF; Kaiano JH; Camargo LP; Vêncio RZ; Snitcovsky IM; Makdissi FB; e Silva PJ; Góes JC; Brentani MM
    Clin Cancer Res; 2005 Oct; 11(20):7434-43. PubMed ID: 16243817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.